Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 254

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 19
Chunk 254
---
112      $              350,400      ( 78,500      ( 68,624      289,388  

  Xylo Technologies      $                193,750      $              $              $                  ( 107,638      $            
  Ltd. – shares (2)                                                                                                                 
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                         October 31,                   Additions      Disposals      Changes                           October 31,  

  (1)      On                                                                                                                                        
           October 30, 2024, the Company subscribed for 80,000 shares and 240,000 warrants (“ Polyrizon Warrants”) of Polyrizon Ltd.                 
           (“ Polyrizon”) in Polyrizon’s initial public offering on the Nasdaq at a cost of $ 350,400. Each Polyrizon Warrant can                    
           be exercised into one ordinary share of Polyrizon at an exercise price of $ 4.38 per share. The Polyrizon Warrants expire on October 29,  
           2029. The fair value of the Polyrizon Warrants as of October 31, 2024, was $ 178,988 based on the Block-Scholes option pricing model,     
           using the following assumptions: risk-free rate of 4.28%, expected life of 5 years and volatility of 92%. See note 19a.                   
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  (2)      Pursuant                                                                                                                       

During
the year ended October 31, 2024, the Company sold all its remaining shares of Xylo, for total proceeds of $ 78,500 7,612

F-20

CLEARMIND
MEDICINE INC.

Notes to
the Consolidated Financial Statements

(Expressed
in United States Dollars)

  Related             

  Compensation to key management  

  (i)      The compensation to key management personnel for employment services they provide to the Company is as follows:  

                                 Year ended                    Year ended                    Year ended                  
                                 October 31,                   October 31,                   October 31,                 
                                 2024                          2023                          2022                        
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Officers:                                                                                                              
  Payroll and                    $                      -      $                      -